

**Date and Time:** *Friday 8<sup>th</sup> November 2013*

**Minutes:** confirmed

**Guideline Development Group Meeting 9: Dyspepsia & GORD**

**Place:** NICE office, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BD

**Present:** Peter Barry (Chair) (PB)  
 Hugh Barr (HB)  
 John de Caestecker (JD)  
 Mark Follows (MF)  
 Ann Harding (AH)  
 Janusz Jankowski (JJ)  
 Mimi McCord (MM)  
 Tin Siuman (TS)

**Apologies:** Alex Ford (AF)

<p><b>In attendance:</b>                  NICE Staff:</p> <p>Emma Banks (EB)                  Ben Doak (BD)                  Ruth Garnett (RG)                  Michael Heath (MH)</p>	<p>Sarah Palombella (SP)                  Gabriel Rogers (GR)                  Toni Tan (TT)                  Jonathan Underhill (JU)</p>	<p><b>Apologies:</b>                  Rachel Houten (RH)</p>
--	---	--

**Notes**

1. PB welcomed the group to the 9<sup>th</sup> meeting of this GDG. Apologies were received from AF. Minutes for the previous meeting were agreed without amendment.
2. All GDG members were asked to share any new conflicts of interest which have not been previously declared. No new conflicted were declared. In addition no new conflicts were declared by the NICE team.
3. SP reminded the group about the role the Editor, highlighting how she will support the GDG and NICE technical team during the final stages of development. She went on to explain the different formats the guidance will take. In addition to the Full guideline there would be a NICE pathway, Information for the public and NICE guideline and the GDG were provided with details about what these products would contain and who they were for. Finally, a request was made for volunteers to provide support and input to the development of the NICE pathway and the Information for the public guidance.

## Notes

4. The group then reviewed work carried out to date, paying particular attention to the linking evidence to recommendations sections and the recommendations themselves to ensure that the discussions of the evidence and GDG experiences are reflected correctly to support each recommendation.
5. The afternoon session was spent discussing the health economics model for review question 4 which asks *what is the clinical effectiveness of PPIs in patients with severe erosive reflux disease*. GR reminded the group of the clinical evidence available and its limitations, particularly around dosage. He then took the group through the network meta-analysis carried out for both the healing and maintenance phases of the disease and then the application of these results within the model. GR summarised the assumptions discussed and agreed at the last meeting and took further feedback and additional input from the group. GR confirmed this information would be applied to the model and the group would review and discuss the model and its outputs at the next meeting.
6. PB closed the meeting and thanked everyone for attending.

### **Date and venue of the next meeting:**

Next Meeting: 14<sup>th</sup> & 15<sup>th</sup> January 2014 at Red Rooms, Manchester, M2 3AW